SCHEMBL5768587

SCHEMBL5768587

CN1Cc2cc([N+](=O)[O-])ccc2C(C)(C)C1

nearest known ligand 0.43

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.43
SIRT6 Q8N6T7 1/20 0.43
TDP2 O95551 1/20 0.42
PNMT P11086 6/20 0.42
ADRA2A P08913 4/20 0.42
ADRA2B P18089 3/20 0.42
ADRA2C P18825 3/20 0.42
DPP7 Q9UHL4 1/20 0.41
MEN1 O00255 1/20 0.41
MAPT P10636 1/20 0.41
RAB9A P51151 1/20 0.41
KMT2A Q03164 1/20 0.41
TLR9 Q9NR96 1/20 0.41
ALDH1A1 P00352 3/20 0.40
POLB P06746 1/20 0.40
AKR1B1 P15121 1/20 0.39
SIRT2 Q8IXJ6 1/20 0.39
HPGD P15428 1/20 0.39
HIF1A Q16665 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1679785 0.85 LMNA (0.41) LMNASIRT6TDP2PNMTADRA2A
Hydrochloric Acid SCHEMBL1679182 0.84 KDM4E (0.43) LMNASIRT6TDP2PNMTADRA2A
SCHEMBL12005303 0.81 PNMT (0.43) LMNATDP2PNMTADRA2AADRA2B
SCHEMBL29945643 0.80 DPP7 (0.50) LMNASIRT6TDP2PNMTADRA2A
SCHEMBL28408084 0.80 DPP7 (0.46) LMNATDP2PNMTADRA2AADRA2B
SCHEMBL444981 0.80 DPP7 (0.46) LMNATDP2PNMTADRA2AADRA2B
SCHEMBL27565587 0.80 DPP7 (0.44) LMNATDP2PNMTADRA2AADRA2B
SCHEMBL27565590 0.80 DPP7 (0.39) LMNATDP2PNMTADRA2AADRA2B
SCHEMBL1952644 0.78 TDP2 (0.44) LMNASIRT6TDP2PNMTADRA2A
Bromoethane SCHEMBL14060023 0.78 PNMT (0.40) LMNATDP2PNMTADRA2AADRA2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4642767-A1 PYRIMIDINE CARBOXAMIDE COMPOUNDS Acrivon Therapeutics, Inc. (US) 2025-11-05 EP disclosed
EP-4619406-A1 TRICYCLIC COMPOUNDS Schrödinger, Inc. (US) 2025-09-24 EP disclosed
WO-2024145505-A1 PYRIMIDINE CARBOXAMIDE COMPOUNDS ACRIVON THERAPEUTICS, INC. (US) 2024-07-04 WO disclosed
WO-2024107393-A1 TRICYCLIC COMPOUNDS SCHRÖDINGER, INC. (US) 2024-05-23 WO disclosed
EP-3661918-B1 1,2-DIHYDRO-3H-PYRAZOLO[3,4-D]PYRIMIDIN-3-ONE ANALOGS RECURIUM IP HOLDINGS LLC (US) 2024-05-08 EP disclosed
US-20210317124-A1 1,2-DIHYDRO-3H-PYRAZOLO[3,4-D]PYRIMIDIN-3-ONE ANALOGS RECURIUM IP HOLDINGS, LLC 2021-10-14 US disclosed
US-11124518-B2 L,2-dihydro-3H-pyrazolo[3,4-D]pyrimidin-3-one analogs RECURIUM IP HOLDINGS, LLC (US) 2021-09-21 US disclosed
EP-3661918-A1 1, 2 - DIHYDRO- 3H- PYRAZOLO [3, 4 - D]PYRIMIDIN -3 - ONE ANALOGS Recurium IP Holdings, LLC (US) 2020-06-10 EP disclosed
US-20200157112-A1 1,2-DIHYDRO-3H-PYRAZOLO[3,4-D]PYRIMIDIN-3-ONE ANALOGS RECURIUM IP HOLDINGS, LLC 2020-05-21 US disclosed
CN-111094253-A 1, 2-dihydro-3H-pyrazolo [3,4-d ] pyrimidin-3-one analogs 里科瑞尔姆IP控股有限责任公司 2020-05-01 CN disclosed
CN-110467615-A Azolopyrimidines include its pharmaceutical composition and its preparation method and application SICHUAN KELUN BOTAI BIOMEDICAL CO LTD 2019-11-19 CN disclosed
WO-2019028008-A1 1, 2 - DIHYDRO- 3H- PYRAZOLO [3, 4 - D] PYRIMIDIN -3 - ONE ANALOGS Zeno Royalties & Milestones, LLC (US) 2019-02-07 WO disclosed
EP-1678173-A2 4-HETEROBICYCLYLAMINO-SUBSTITUTED QUINAZOLINES AND ANALOGUES THEREOF AS CAPSAICIN-ANTAGONISTS NEUROGEN CORPORATION (US) 2006-07-12 EP disclosed
WO-2005023807-A2 4 - HETEROBICYCLYAMINO - SUBSTITUTED QUINAZOLINES AND ANALOGUES THEROF AS CAPSAICIN - ANTAGONISTS NEUROGEN CORPORATION (US) 2005-03-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200157112-A1 1,2-DIHYDRO-3H-PYRAZOLO[3,4-D]PYRIMIDIN-3-ONE ANALOGS MKI67, BRCA1, CDK4 LMNA 3995/4885SIRT6 2407/4885TDP2 2036/4885
US-20210317124-A1 1,2-DIHYDRO-3H-PYRAZOLO[3,4-D]PYRIMIDIN-3-ONE ANALOGS MKI67, BRCA1, CDK4 LMNA 3995/4885SIRT6 2407/4885TDP2 2036/4885
US-11124518-B2 L,2-dihydro-3H-pyrazolo[3,4-D]pyrimidin-3-one analogs MKI67, BRCA1, CCND1 LMNA 2055/4885SIRT6 2299/4885TDP2 1629/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.